Biodexa Pharmaceuticals Plc

Biodexa Pharmaceuticals PLC operates as a clinical-stage biopharmaceutical company, concentrating its efforts on developing innovative products for the treatment or prevention of gastrointestinal cancers, specifically gastrointestinal stromal tumors (GIST) and familial adenomatous polyposis (FAP) ¹. The company's core business model revolves around developing clinical assets to a proof-of-concept stage, after which it intends to license these products to partners for late-stage development, marketing, and sales ². Revenue generation is expected primarily through product royalties and milestone payments from these licensing deals ³. The company has generated minimal revenue from its product candidates to date ⁴.

The company's product pipeline includes eRapa, MTX240, and tolimidone. eRapa, a proprietary oral tablet formulation of rapamycin, is an mTOR inhibitor designed to address poor bioavailability and toxicity associated with existing rapamycin forms ⁵. It is being developed for FAP and Non-Muscle Invasive Bladder Cancer (NMIBC) ⁶. MTX240, a new chemical entity molecular glue licensed from Otsuka, is initially intended for GIST treatment ⁷. Tolimidone, a selective activator of the enzyme lyn kinase, is being developed for Type 1 Diabetes (T1D) ⁸. Due to resource constraints, MTX110, a panobinostat formulation for aggressive rare/orphan brain cancer, has been de-prioritized ⁹. The company has also closed its laboratory in Cardiff, Wales, and is no longer investing in its drug delivery technologies, including Q-Sphera, MidaSolve, and MidaCore ¹⁰.

For the fiscal year ended December 31, 2025, Biodexa Pharmaceuticals PLC reported total revenue of £Nil ¹¹, consistent with the £Nil reported in 2024 ¹². The company incurred a net loss of £6.25 million in 2025 ¹³, compared to a net loss of £5.73 million in 2024 ¹⁴ and £7.08 million in 2023 ¹⁵. The accumulated deficit as of December 31, 2025, was £155.67 million ¹⁶. Research and development costs decreased to £3.96 million in 2025 ¹⁷ from £5.44 million in 2024 ¹⁸, representing a 27% reduction ¹⁹. Administrative costs, however, increased by £1.04 million, or 27%, to £4.84 million in 2025 ²⁰ from £3.79 million in 2024 ²¹. Finance income in 2025 was £2.385 million ²², which included a £2.30 million gain on an equity-settled derivative financial liability ²³. Finance expense for 2025 was £229 thousand ²⁴. As of December 31, 2025, cash and cash equivalents stood at £8.53 million ²⁵.

Year-over-year comparisons show a significant reduction in R&D costs, primarily driven by a £0.71 million decrease in MTX228 preclinical studies and manufacturing costs, a £0.60 million reduction in the MTX110 MAGIC-G1 study, and a £0.44 million decrease in MTX230 eRapa costs (net of grant income) ²⁶. The percentage of MTX230 (eRapa) costs offset by grant funding increased to 77% in 2025 from 43% in 2024 ²⁷. Conversely, administrative costs rose by £1.04 million, or 27%, mainly due to a £0.44 million foreign exchange movement and a £0.73 million increase in professional fees, partially offset by a £0.10 million reduction in share-based payments ²⁸. The company's finance income saw a decrease from £3.385 million in 2024 to £2.385 million in 2025 ²⁹.

Significant operational developments during the period include the licensing of eRapa in April 2024 from Emtora Biosciences, Inc. ³⁰, and MTX240 in February 2026 from Otsuka Pharmaceutical Co., Ltd ³¹. The FDA granted fast track designation for eRapa on February 10, 2025 ³². An additional grant of $3.0 million from CPRIT was received in May 2025 to support the registrational Phase 3 program of eRapa in FAP ³³. The first clinical study site for the Phase 3 eRapa trial in FAP was activated on June 25, 2025 ³⁴, with the filing of a Clinical Trial Application (CTA) with the EMA on July 14, 2025 ³⁵, and the enrollment of the first two patients on August 18, 2025 ³⁶. The EMA approved the CTA for the Phase 3 study in Europe on November 3, 2025 ³⁷, and the first European patients were enrolled on December 1, 2025 ³⁸. As of March 16, 2026, there were 22 active clinical sites and 37 patients enrolled in the Phase 3 study ³⁹. The company also initiated a Phase 2a dose confirmation study for tolimidone in T1D, with the first patient recruited on June 4, 2025 ⁴⁰.

Management's cash flow forecasts indicate that further financing will be required before the third quarter of 2026, assuming current development programs and operating activities continue as planned ⁴¹. The company has entered into a $35.0 million equity line of credit (ELOC) agreement in January 2025 with C/M Capital Master Fund LP, under which it may direct the investor to purchase Depositary Shares ⁴². To date, $8.92 million of shares have been sold under the ELOC ⁴³.

A major growth area for the company is the continued development of eRapa for FAP. The Phase 3 study of eRapa in FAP is a double-blind placebo-controlled trial involving 168 patients, randomized 2:1 drug/placebo, across approximately 30 clinical sites in the United States and Europe ⁴⁴. The primary endpoint for this study is time to a defined progression-free survival event ⁴⁵. The company expects that prior grants and an additional $3.0 million grant from CPRIT received in May 2025 will substantially fund all costs of this Phase 3 study ⁴⁶. As of March 16, 2026, 22 active clinical sites and 37 patients were enrolled in the Phase 3 study ⁴⁷. The FDA granted fast track designation for eRapa on February 10, 2025, which is intended to facilitate development and expedite review for serious conditions with unmet medical needs ⁴⁸.

Another significant growth vector is MTX240, a new chemical entity molecular glue licensed from Otsuka in February 2026, which the company intends to develop initially for GIST ⁴⁹. The first priority for MTX240 is to engage a contract manufacturer for clinical trial material, file an IND application, and commence a Phase 1b/2a dose escalation study to determine a maximum tolerated dose and preferred regimen, followed by an extension component to assess potential efficacy signals in TKI-resistant patients ⁵⁰. The goal is to dose the first patient in this study by the end of 2026 ⁵¹. The global GIST market is valued at approximately USD 1.3 billion and is projected to grow at 6-10% annually through 2032 ⁵². MTX240 benefits from composition of matter patents in the United States, Europe, Japan, and other countries extending through 2037, without patent term extension ⁵³.

The operational outlook includes a continued focus on developing clinical assets to proof-of-concept stage before seeking licensing partners ⁵⁴. The company does not intend to establish its own manufacturing capabilities, instead utilizing GMP-certified contract manufacturers for clinical trial material ⁵⁵. The company's strategy involves building a balanced portfolio of clinical-stage development assets, ideally with a focus on rare/orphan indications in gastrointestinal/oncology ⁵⁶.

Planned capital allocation includes continued investment in research and development for eRapa, MTX240, and tolimidone ⁵⁷. The company has already sold 57,648,000,000 Ordinary Shares under the ELOC, generating gross proceeds of approximately $8.9 million, and issued 1,840,460,000 Ordinary Shares as a commitment fee ⁵⁸.

Management has explicitly flagged the requirement for additional financing in the short-term as a material uncertainty that raises substantial doubt about the company's ability to continue as a going concern ⁵⁹. The company believes its existing cash and cash equivalents of £8.53 million as of December 31, 2025, will be insufficient to satisfy working capital needs and other liquidity requirements over the next 12 months ⁶⁰. There is no guarantee that the ELOC can be fully utilized to finance operations ⁶¹. The environment for financing small and micro-cap biotech companies remains challenging, which may lead to dilutive financing options if acquisitions or mergers are pursued ⁶². Geopolitical risks, including ongoing conflicts and economic sanctions, could disrupt global markets, increase volatility, and negatively impact the company's business and supply chain ⁶³. Tariff policies and potential countermeasures could increase costs and disrupt the supply chain ⁶⁴. Currency exchange rate fluctuations, particularly between the British pound sterling, Euros, and the United States dollar, could significantly affect operating results ⁶⁵.

The company faces material risks including the requirement for additional short-term financing, which raises substantial doubt about its ability to continue as a going concern, as existing cash and cash equivalents of £8.53 million ⁶⁶ are insufficient for the next 12 months of operations ⁶⁷. The inability to fully utilize the $35.0 million ⁶⁸ equity line of credit (ELOC) or secure other financing on favorable terms could significantly harm the business ⁶⁹. The early-stage nature of operations means no recurring revenue sources, and there is no assurance of successfully developing and licensing product candidates or achieving profitability ⁷⁰. Political, regulatory, social, and economic risks related to the United Kingdom's exit from the European Union could increase complexity and restrict access to capital ⁷¹. The lengthy, time-consuming, and unpredictable regulatory approval processes in the United States and Europe, coupled with the inherent uncertainty of clinical trial outcomes, could delay or prevent market approval for product candidates ⁷². Undesirable side effects from product candidates could halt clinical trials or lead to restrictive labeling or denial of regulatory approval ⁷³. Geopolitical risks, including ongoing conflicts and economic sanctions, could disrupt global markets and supply chains ⁷⁴. Cybersecurity incidents, including data breaches and system failures, pose risks to confidential information and could result in operational disruptions, litigation, and significant costs ⁷⁵. Compliance with evolving global data protection laws, such as GDPR and UK GDPR, carries substantial costs and risks of significant penalties, including fines up to €20 million (or £17.5 million under the UK GDPR) or up to 4% of total worldwide annual turnover ⁷⁶.

Management's message to shareholders conveys a strategic re-positioning of the company as a therapeutics-focused entity, moving away from drug delivery technologies, with a primary focus on delivering proof-of-concept clinical data for its pipeline assets. The company explicitly states that further financing will be required before the third quarter of 2026, assuming current development programs continue as planned ⁷⁷. Management believes there are adequate options and time available to secure additional financing, including equity sales through the existing $35.0 million ELOC ⁷⁸, and has a history of successful fundraising. The three strategic priorities emphasized for the period ahead are: building a balanced portfolio of clinical-stage development assets, ideally with a focus on rare/orphan indications in gastrointestinal/oncology; developing clinical assets to proof-of-concept stage before securing partners for later-stage development, with the exception of eRapa which is being developed through Phase 3 to potential registration due to $20.0 million in grant funding from CPRIT ⁷⁹; and utilizing GMP-certified contract manufacturers for clinical trial material rather than establishing in-house manufacturing capabilities.